tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNYResearch Report), Cigna (CIResearch Report) and SCYNEXIS (SCYXResearch Report).

Alnylam Pharma (ALNY)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $200.00. The company’s shares closed last Thursday at $150.86.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 14.0% and a 43.9% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals.

Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $210.20, implying a 41.9% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $208.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cigna (CI)

Morgan Stanley analyst Ricky Goldwasser maintained a Hold rating on Cigna yesterday and set a price target of $235.00. The company’s shares closed last Thursday at $230.27.

According to TipRanks.com, Goldwasser is a 5-star analyst with an average return of 14.5% and a 65.1% success rate. Goldwasser covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Bright Health Group, and Oak Street Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cigna with a $254.77 average price target, a 10.7% upside from current levels. In a report issued on February 4, Deutsche Bank also downgraded the stock to Hold with a $236.00 price target.

SCYNEXIS (SCYX)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on SCYNEXIS today and set a price target of $22.50. The company’s shares closed last Thursday at $5.11, close to its 52-week low of $4.21.

According to TipRanks.com, Higgins is a 3-star analyst with an average return of 5.0% and a 31.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Armata Pharmaceuticals, and Viridian Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SCYNEXIS with a $19.50 average price target, representing a 298.0% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed